The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: A systematic review and meta-analysis

Yong-chao Qiao$^{1,2,*}$, Yin-ling Chen$^{1,3,*}$, Yan-hong Pan$^{1,3}$, Fang Tian$^2$, Yan Xu$^2$, Xiao-xi Zhang$^{1,3}$, Hai-lu Zhao$^{1,2,3,*}$

$^1$ Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, China, $^2$ Department of Immunology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China, $^3$ Department of Immunology, Faculty of Basic Medicine, Guilin Medical University, Guilin, China

* These authors contributed equally to this work.

® zhaohailu9@126.com

Abstract

Objective
The aim of this study was used meta-analysis to investigate changes of serum tumor necrosis factor-alpha (TNF-α) in patients with type 1 diabetes mellitus (T1DM).

Methods
Relevant literatures were identified from PubMed, Cochrane Library, CNKI, WanFang and Chinese-Cqvip databases (published from January 1, 1999 to September 30, 2016). Eligible reports were included for pooled analysis of serum TNF-α level and subgroup analysis was performed in relation with age, disease duration and ethnicity.

Results
A total of 23 articles (1631 T1DM cases, 1429 healthy controls) were included for this meta-analysis. Compared with the controls, the patients had significantly increased serum TNF-α level ($P < 0.001$). Similar results were also found among all subgroup analysis of different age, disease duration and ethnicity (with the exception of Asian) ($P < 0.05$). Regression analysis indicated that age ($P = 0.680$), disease duration ($P = 0.957$), and ethnicity ($P = 0.526$) of patients were not significant impact factors for the high heterogeneity. The results were stable according to the sensitivity analysis and no publication bias existed in this meta-analysis.

Conclusions
Serum TNF-α level in T1DM patients has significantly elevated among all age, disease duration and ethnicity groups.
Introduction

Type 1 diabetes mellitus (T1DM) is a systemic disease leading to abnormal fat, carbohydrate, and protein metabolism due to insulin deficiency [1]. Metabolic proinflammatory disorder, such as chronic hyperglycemia and increased levels of circulating cytokines, suggests immunological disturbances [2–5], which seriously affects the quality of life of the patients and imposes a large economic burden on the national health care system [6]. The reasons responsible for this disease are almost summarized as genetic and environmental factors.

The role of inflammation in diabetes mellitus (DM) has recently been implicated [7] and that inflammatory reaction, mediated by acute phase proteins and cytokines, could lead to the prevention or promotion of diabetes [8, 9]. Inflammatory cytokines such as interleukine-6 (IL-6) [10, 11], IL-17 [12, 13], transforming growth factor-beta (TGF-β) [14] and C-reactive protein (CRP) [15] have been shown to be elevated in DM patients, and the elevated cytokines play an important role in the development and progression of cardiovascular complications.

Tumor necrosis factor-alpha (TNF-α) produced by activated macrophages, CD4+ lymphocytes, natural killer cells, neutrophils, mast cells, eosinophils and neurons, is a cytokine involved in systemic inflammation and always results in acute phase reaction [16]. TNF-α may induce insulin resistance through direct effects on the insulin signaling pathway, and thus participates in the pathogenesis of type 2 DM and obesity [17–20]. As an endogenous factor, TNF-α not only influences energy balance, but also is associated with weight loss, hypermetabolism and resting energy expenditure in malignant diseases [21]. Many researchers focus on the change of serum TNF-α level [21–26] in DM patients, yet findings are inconsistent. In the present study, we performed a pooled analysis of data to define the change of serum TNF-α in T1DM patients.

Methods

Search strategies

This study was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria [27]. The work described here was performed in accordance with the Declaration of Helsinki. This study was approved by the Ethical Committee of Guilin Medical University. We systematically searched five databases (PubMed, Cochrane Library, CNKI, WanFang and Chinese-Cqvip) about the studies published from January 1, 1999 to September 30, 2016. The search strategy using medical terms as following: (“tumor necrosis factor alpha” or “TNF-α”) and (“type 1 diabetes” or “diabetic patients” or “diabetes mellitus” or “DM” or “T1DM”). Otherwise, we identified the additional reports through references cited in recruited articles.

Inclusion criteria and exclusion criteria

All related articles were reviewed using the criteria as follows: (1) Studies focusing on the change of serum TNF-α level in T1DM patients; (2) Case-control research; (3) Patients used insulin alone; (4) Data expressed as Mean ± SD; and (5) Definitions of T1DM met the criteria recommended by the World Health Organization [28].

Exclusion criteria: (1) For duplicated studies and reports, we only included the latest paper into our final analysis; (2) Animal studies, reviews, editorials, case reports, and personal experience summaries; (3) No healthy controls in the study; (4) Original data displayed as figures or no original data reported; and (5) Inconsistent with the inclusion criteria as described above.
Quality assessment and data extraction

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of all eligible studies [29] and the following information from each eligible study was extracted independently by two reviewers: (1) first author’s surname; (2) date of publication; (3) country of the studied population; (4) mean age of patients; (5) sample size of case-control; (6) mean disease duration of patients; (7) Mean ± SD displayed the level of serum TNF-α. Considering disagreement, we invited the third investigator to assess such articles through discussion.

Statistical analysis

We extracted the data (sample size, Mean ± SD) to clarify the change of TNF-α in T1DM patients versus controls, followed by Chi-squared Q test and I² statistics to estimate the heterogeneity [30, 31]. When \( P < 0.1 \) or I² > 50%, we selected a random-effect model to account for possible heterogeneity between studies; otherwise a fixed-effect model was used in the absence of heterogeneity [32, 33]. In order to evaluate the age and disease duration impact on serum TNF-α, all the patients in the included studies were stratified into three groups by age (<12, 12–24, >24 years old) and by disease duration (<5, 5–10, >10 years) respectively. And the impact of different ethnicity of patients was explored by subgroup analysis of five ethnicity groups (Asia, Europe, America, Africa and Oceania). Regression analysis was used to investigate sources of heterogeneity. In addition, we conducted sensitivity analysis by excluding individual studies or selecting articles with high NOS score (≥) or changing the Cochran’s Q statistic methods to check the stability of the results. Publication bias was judged by an Egger’s test (\( P < 0.05 \) was considered representative of statistically significant publication bias) [34]. Stata 12.0 software was used in this pooled analysis.

Results

The process and results of selection

The study selection process was displayed in Fig 1. With our search criteria, we collected 3397 potential studies and excluded 1074 due to duplication. After reading the titles and abstracts, 2226 articles were excluded for no controls, not DM relevant, review and editorial articles or animal studies. Then, we excluded 76 articles due to original data expressed with figures, duplicated data, or no original data. Finally, 20 articles (23 case-control studies) met the criteria and were included in this meta-analysis [1, 7, 21–25, 35–47] (S1 Appendix), involving 1631 T1DM patients and 1429 healthy controls. The specific characteristics of the 23 studies are shown in Table 1.

Results of meta-analysis and subgroup analysis

The T1DM patients had significantly increased serum TNF-α level compared with the controls (SMD, 1.23; 95% CI, 0.77 to 1.68; \( P < 0.001 \)) (Fig 2) and significant heterogeneity (\( P < 0.001 \)) existed in this meta-analysis.

In the subgroup analysis by age, disease duration, and ethnicity, T1DM patients consistently had significantly increased levels of TNF-α among the three age groups (all \( P < 0.01 \)) (Fig 3), and three disease duration groups (all \( P < 0.05 \)) (Fig 4), and four ethnicity subgroups (all \( P < 0.05 \)) except Asia group (SMD, 0.67; 95% CI, -1.03 to 2.36; \( P = 0.439 \)) (Fig 5).

Regression analysis

Regression analysis was used to explore the source of high heterogeneity of age, disease duration, and ethnicity for the serum level of TNF-α, and the results displayed as follows: age (t = -0.42; 95% CI, -1.035 to 0.689; \( P = 0.680 \)), disease duration (t = -0.06; 95% CI, -1.091 to 1.036;
$P = 0.957)$, and ethnicity of patients ($t = 0.64; 95\%$ CI, -0.298 to 0.567; $P = 0.526$), which indicated that age, disease duration, and ethnicity of patients were not significant impact factors for the high heterogeneity in this meta-analysis.

**Sensitivity analysis**

We first performed sensitivity analysis by excluding individual studies and found the results remaining consistent (Fig 6A). Next, sensitivity analysis was conducted by selecting studies...
with high NOS score (≥) or excluding studies with high risk of bias and we found that all the outcomes still had no significant changes. Otherwise, fixed effects model was chosen to pool the data, all the results were similar to those generated by random effects model.

### Publication bias

Egger’s test showed that no publication bias existed in this meta-analysis (t = 2.04; P = 0.054; 95% CI, -0.074 to 7.370) (Fig 6B).

Table 1. Characteristics of studies about serum TNF-α (ng/L) included in this meta-analysis.

| Author | Year | Country | Methods | Duration (years) | Case | Control | NOS score |
|--------|------|---------|---------|------------------|------|---------|-----------|
| Hegazy[35] | 2013 | Egypt | ELISA | 4.3±2.1 | 15 | 7/8 | 11.1±2.3 | 9 | 9 | 15 | 7/8 | 11.5±1.4 | 5.4 | 1.7 | 8 |
| Hegazy[35] | 2013 | Egypt | ELISA | 4.4±3.0 | 15 | 7/8 | 11.9±1.4 | 9.1 | 9 | 15 | 7/8 | 11.5±1.4 | 5.4 | 1.7 | 8 |
| Yuan[36] | 2010 | China | ELISA | NR | 15 | NR | 18.53±8.70 | 36.47 | 16.33 | 90 | NR | 28.33±6.12 | 35.37 | 14.97 | 6 |
| Poplawska[1] | 2014 | Poland | ELISA | NR | 62 | NR | 42.6±12.7 | 1.6 | 1.2 | 6 | NR | 48.3±2.1 | 0.8 | 0.5 | 6 |
| Talata[37] | 2016 | Saudi Arabia | FCM | 3.50±0.39 | 250 | NR | 8.50±0.5 | 19.81 | 8.75 | 250 | NR | 8.50±0.5 | 3.22 | 0.45 | 7 |
| Balic a[38] | 2009 | Chile | ELISA | 0.21±0.12 | 300 | 15/142 | 10.8±4.1 | 2.31 | 36.8 | 310 | 146/164 | 11.0±2.2 | 1.39 | 0.88 | 8 |
| Balic a[38] | 2009 | Chile | ELISA | 0.21±0.12 | 300 | 15/142 | 10.8±4.1 | 5.22 | 31.7 | 310 | 146/164 | 11.0±2.2 | 1.23 | 1.08 | 8 |
| Machnica[39] | 2014 | Poland | ELISA | 5.09±1.97 | 52 | 19/33 | 14.07±3.03 | 16.63 | 8.32 | 20 | 8/12 | 13.09±3.05 | 9.41 | 4.23 | 8 |
| Alexandr i b[7] | 2008 | Athens | ELISA | 11.87±2.36 | 20 | 13/7 | NR | 0.67 | 0.27 | 34 | 17/17 | NR | 0.53 | 0.29 | 7 |
| Romano a[40] | 2001 | Italy | ELISA | 0.35±0.32 | 20 | 11/9 | 10.6±3.4 | 21.9 | 9.48 | 10 | 6/4 | 9.6±2.6 | 4.4 | 1.68 | 7 |
| Araya[25] | 2003 | Chile | ELISA | 12.0±5.9 | 15 | 8/7 | 22.2±3.1 | 5.7 | 1.5 | 14 | 5/9 | 25.1±3.7 | 1.3 | 0.2 | 8 |
| Mitrovic c[41] | 2011 | Serbia | ELISA | 20.01±8.78 | 76 | 32/44 | 35.24±11.09 | 0.65 | 0.37 | 30 | 12/18 | 38.10±12.97 | 0.2 | 0.11 | 8 |
| Pham c[42] | 2011 | Germany | ELISA | 0.1±0.40 | 90 | 62/28 | 43.2±4.45 | 2.4 | 0.5 | 41 | 16/25 | 47.7±3.38 | 1.8 | 0.35 | 7 |
| Pertynska[22] | 2010 | Poland | ELISA | 9.5±5.41 | 14 | 0/14 | 27.06±10.35 | 5.19 | 8.81 | 16 | 0/16 | 25.21±4.21 | 9.69 | 21.25 | 8 |
| El-Samah y[24] | 2015 | Scotland | ELISA | 6.1±1.6 | 32 | 12/20 | 12.4±2.6 | 17.6 | 1.9 | 30 | 11/19 | 13.4±1.9 | 6.5 | 1.22 | 8 |
| Martos[43] | 2006 | Spain | ELISA | NR | 20 | 10/10 | 7.3±0.88 | 3 | 3.1 | 40 | 20/20 | 8.16±0.46 | 1.4 | 1.2 | 7 |
| Aguilera[44] | 2015 | Spain | ECMA | 20.4±8.1 | 150 | NR | 38.6±8.1 | 7.5 | 2.4 | 50 | NR | 38.1±7.2 | 7.8 | 1.8 | 7 |
| Gabbay[45] | 2012 | Brazil | FCM | NR | 25 | NR | 13.6±5.4 | 9.69 | 21.25 | 8 |
| Lo[23] | 2004 | Taiwan | ELISA | NR | 58 | 22/36 | 10.98±4.61 | 11.15 | 14.34 | 33 | 16/17 | 10.06±4.90 | 14.22 | 17.92 | 8 |
| Abdel[46] | 2001 | Egypt | ECMA | 5.48±3.22 | 15 | 8/7 | 13.71±4.26 | 14 | 10.67 | 15 | 8/7 | 13.21±3.20 | 6.61 | 1.97 | 8 |
| Lechleitner[21] | 2000 | Austria | ELISA | 12.8±8.1 | 29 | 29/0 | 31.7±6.0 | 19.9 | 8.4 | 24 | NR | 30.5±6.8 | 11.1 | 5.8 | 7 |
| Lechleitner[21] | 2000 | Austria | ELISA | 8.1±7.7 | 15 | 0/15 | 29.3±6.4 | 18.3 | 5.2 | 24 | NR | 30.5±6.8 | 11.1 | 5.8 | 7 |
| Lv[47] | 2013 | China | ELISA | 0.16±0.08 | 33 | 18/15 | 12±4 | 27 | 14 | 27 | 15/12 | 11±4 | 26 | 6 | 8 |

FCM, flow cytometry method; ELISA, enzyme-linked immunosorbent assay; ECMA, enzyme chemiluminescence immunometric assay; SZ, sample size; M/F, male/female; SD, standard deviation; NR, not report.

a Data converted from median (range).

b SD data converted from SE.

c Data converted from median (interquartile range).

https://doi.org/10.1371/journal.pone.0176157.t001
**Discussion**

TNF-α is highly involved with macrophage activation and increased serum TNF-α level have been observed in insulin resistance stages and diabetes mellitus development [48], however, inconsistency still existed and no meta-analysis was conducted about the change of serum TNF-α level in T1DM patients. The results of this study clearly demonstrate that T1DM patients had significantly elevated serum level of TNF-α and significant correlation existed between TNF-α level and patients’ age, disease duration and ethnicity.

TNF-α level may play an important role and many factors may contribute to the serum TNF-α level in diabetes. TNF-α, as the major physiological and pathophysiological regulators of vascular adhesion molecules, is a key proinflammatory cytokine with widespread metabolic effects, and directly regulate the production of several cardiovascular risk factors [49, 50].

| Study ID                  | SMD (95% CI)          | Weight % |
|---------------------------|-----------------------|----------|
| Hegazy et al. (2013)      | 2.65 (1.65, 3.64)     | 3.91     |
| Hegazy et al. (2013)      | 2.72 (1.71, 3.73)     | 3.89     |
| Yuan et al. (2010)        | 0.07 (-0.47, 0.62)    | 4.50     |
| Poplawska et al. (2014)   | 0.69 (-0.16, 1.53)    | 4.13     |
| Talaat et al. (2016)      | 2.68 (2.44, 2.92)     | 4.75     |
| Balic et al. (2009)       | 0.04 (-0.12, 0.19)    | 4.79     |
| Balic et al. (2009)       | 0.18 (0.02, 0.34)     | 4.79     |
| Machnica et al. (2014)    | 0.97 (0.43, 1.51)     | 4.51     |
| Alexandraki et al. (2008) | 0.49 (-0.07, 1.06)    | 4.49     |
| Romano et al. (2001)      | 2.22 (1.27, 3.18)     | 3.97     |
| Araya et al. (2003)       | 4.04 (2.74, 5.34)     | 3.46     |
| Mitrovic et al. (2011)    | 1.41 (0.94, 1.87)     | 4.59     |
| Pham et al. (2011)        | 1.31 (0.91, 1.71)     | 4.64     |
| Pertynska et al. (2010)   | -0.27 (-0.99, 0.45)   | 4.30     |
| El-Samahy et al. (2015)   | 6.90 (5.57, 8.24)     | 3.41     |
| Martos et al. (2006)      | 0.79 (0.23, 1.34)     | 4.49     |
| Aguilera et al. (2015)    | -0.13 (-0.45, 0.19)   | 4.70     |
| Gabbay et al. (2012)      | 0.66 (0.14, 1.19)     | 4.52     |
| Lo et al. (2004)          | -0.20 (-0.62, 0.23)   | 4.62     |
| Abdel et al. (2001)       | 0.96 (0.20, 1.72)     | 4.25     |
| Lechleitner et al. (2000) | 1.20 (0.61, 1.79)     | 4.46     |
| Lechleitner et al. (2000) | 1.29 (0.58, 2.00)     | 4.31     |
| Lv et al. (2013)          | 0.09 (-0.42, 0.60)    | 4.54     |
| Overall (I-squared = 96.3%, p = 0.000) | 1.23 (0.77, 1.68) | 100.00 |

Fig 2. Forest plots for the level of serum TNF-α between T1DM patients and healthy controls with random effects model (SMD, 1.23, 95% CI, 0.77 to 1.68, P < 0.001).

https://doi.org/10.1371/journal.pone.0176157.g002
TNF-α via effects on soluble intercellular adhesion molecule-1, may promote vascular adhesion, otherwise plasma levels of TNF-α are associated with dyslipidaemia and increase blood pressure, adding to vascular disease risk, besides, the actions of TNF-α is probably modified by altered production of soluble receptors in type 1 diabetic patients [51]. Increased TNF-α and interleukine-6 (IL-6) levels through metabolic control exist in types 1 and 2 diabetic patients, which suggest that the control of diabetes improves the capacity of activation and maintenance.
of these pro-inflammatory cytokines [52–54]. Other study [21] demonstrated TNF-α levels were elevated in T1DM which was correlated positively with HbA1c and inversely with HDL cholesterol levels. In addition, a significant relationship between TNF-α levels and both BMI and WHR also was observed in analysis of the combined groups [51].

Owning the various biological effects, TNF-α has been proved to have certain catabolic effects on fat cells, and neutralization of TNF-α in obese rats causes a significant increase in the peripheral uptake of glucose in response to insulin, which indicates an important role in the insulin resistance and diabetes that often accompany obesity [55]. TNF-α, through increasing the activities of the NF-κB transcriptional factor [56, 57], protein kinase C [58], amino

| Study ID                         | SMD (95% CI) | Weight % |
|----------------------------------|--------------|----------|
| **Duration (0-5 years)**         |              |          |
| Hegazy et al. (2013)             | 2.65 (1.65, 3.64) | 5.09     |
| Hegazy et al. (2013)             | 2.72 (1.71, 3.73) | 5.07     |
| Talaat et al. (2016)             | 2.68 (2.44, 2.92) | 6.05     |
| Balic et al. (2009)              | 0.04 (-0.12, 0.19) | 6.09     |
| Balic et al. (2009)              | 0.18 (0.02, 0.34) | 6.09     |
| Romano et al. (2001)             | 2.22 (1.27, 3.18) | 5.16     |
| Pham et al. (2011)               | 1.31 (0.91, 1.71) | 5.93     |
| Lv et al. (2013)                 | 0.09 (-0.42, 0.60) | 5.81     |
| **Subtotal (I-squared = 98.3%, p = 0.000)** | 1.43 (0.58, 2.27) | 45.28    |
| **Overall effect (Z = 3.32, p = 0.001)** |           |          |
| **Duration (5-10 years)**        |              |          |
| Machnica et al. (2014)           | 0.97 (0.43, 1.51) | 5.78     |
| Pertynska et al. (2010)          | -0.27 (-0.99, 0.45) | 5.53     |
| El-Samahy et al. (2015)          | 6.90 (5.57, 8.24) | 4.50     |
| Abdel et al. (2001)              | 0.96 (0.20, 1.72) | 5.48     |
| Lechleitner et al. (2000)        | 1.29 (0.58, 2.00) | 5.55     |
| **Subtotal (I-squared = 95.4%, p = 0.000)** | 1.87 (0.31, 3.43) | 26.84    |
| **Overall effect (Z = 2.35, p = 0.019)** |           |          |
| **Duration (> 10 years)**        |              |          |
| Alexandraki et al. (2008)        | 0.49 (-0.07, 1.06) | 5.75     |
| Araya et al. (2003)              | 4.04 (2.74, 5.34) | 4.55     |
| Mitrovic et al. (2011)           | 1.41 (0.94, 1.87) | 5.86     |
| Aguilera et al. (2015)           | -0.13 (-0.45, 0.19) | 6.00     |
| Lechleitner et al. (2000)        | 1.20 (0.61, 1.79) | 5.72     |
| **Subtotal (I-squared = 93.6%, p = 0.000)** | 1.25 (0.31, 2.20) | 27.88    |
| **Overall effect (Z = 2.59, p = 0.009)** |           |          |
| **Overall (I-squared = 97.1%, p = 0.000)** | 1.48 (0.93, 2.02) | 100.00   |
| **Overall effect (Z = 5.28, p < 0.001)** |           |          |

Fig 4. Forest plots about subgroup analysis for the level of TNF-α between T1DM patients and controls with random effects model among different disease duration groups. Duration, 0–5 years, SMD, 1.43, 95% CI, 0.58 to 2.27, P = 0.001; Duration, 5–10 years, SMD, 1.87, 95% CI, 0.31 to 3.43, P = 0.019; Duration, > 10 years, SMD, 1.25, 95% CI, 0.31 to 2.20, P = 0.009; Overall, SMD, 1.48, 95% CI, 0.93 to 2.02, P < 0.001.

https://doi.org/10.1371/journal.pone.0176157.g004
| Study ID          | SMD (95% CI) Weight % |
|------------------|-----------------------|
| **Asia**         |                       |
| Yuan et al. (2010) | 0.07 (-0.47, 0.62) 4.50 |
| Talaat et al. (2016) | 2.68 (2.44, 2.92) 4.75 |
| Lo et al. (2004)   | -0.20 (-0.62, 0.23) 4.62 |
| Lv et al. (2013)   | 0.09 (-0.42, 0.60) 4.54 |
| Subtotal (I-squared = 98.6%, p = 0.000) | 0.67 (-1.03, 2.36) 18.41 |
| Overall effect (Z = 0.77, p = 0.439) |                |
| **Europe**       |                       |
| Poplawksa et al. (2014) | 0.69 (-0.16, 1.53) 4.13 |
| Machnica et al. (2014) | 0.97 (0.43, 1.51) 4.51 |
| Alexandraki et al. (2008) | 0.49 (-0.07, 1.06) 4.49 |
| Romano et al. (2001) | 2.22 (1.27, 3.18) 3.97 |
| Mitrovic et al. (2011) | 1.41 (0.94, 1.87) 4.59 |
| Pham et al. (2011)  | 1.31 (0.91, 1.71) 4.64 |
| Pertynska et al. (2010) | -0.27 (-0.99, 0.45) 4.30 |
| El-Samahy et al. (2015) | 6.90 (5.57, 8.24) 3.41 |
| Martos et al. (2006) | 0.79 (0.23, 1.34) 4.49 |
| Aguilera et al. (2015) | -0.13 (-0.45, 0.19) 4.70 |
| Subtotal (I-squared = 93.8%, p = 0.000) | 1.30 (0.59, 2.01) 43.22 |
| Overall effect (Z = 3.60, p < 0.001) |                |
| **America**      |                       |
| Balic et al. (2009) | 0.04 (-0.12, 0.19) 4.79 |
| Balic et al. (2009) | 0.18 (0.02, 0.34) 4.79 |
| Araya et al. (2003) | 4.04 (2.74, 5.34) 3.46 |
| Gabbay et al. (2012) | 0.66 (0.14, 1.19) 4.52 |
| Subtotal (I-squared = 92.5%, p = 0.000) | 0.67 (0.15, 1.19) 17.55 |
| Overall effect (Z = 2.52, p = 0.012) |                |
| **Africa**       |                       |
| Hegazy et al. (2013) | 2.65 (1.65, 3.64) 3.91 |
| Hegazy et al. (2013) | 2.72 (1.71, 3.73) 3.89 |
| Abdel et al. (2001) | 0.96 (0.20, 1.72) 4.25 |
| Subtotal (I-squared = 81.0%, p = 0.005) | 2.07 (0.86, 3.29) 12.05 |
| Overall effect (Z = 3.34, p = 0.001) |                |
| **Oceania**      |                       |
| Lechleitner et al. (2000) | 1.20 (0.61, 1.79) 4.46 |
| Lechleitner et al. (2000) | 1.29 (0.58, 2.00) 4.31 |
| Subtotal (I-squared = 0.0%, p = 0.845) | 1.24 (0.78, 1.69) 8.77 |
| Overall effect (Z = 5.35, p < 0.001) |                |
| Overall (I-squared = 96.3%, p = 0.000) | 1.23 (0.77, 1.68) 100.00 |
| Overall effect (Z = 5.28, p < 0.001) |                |

**Fig 5.** Forest plots about subgroup analysis for the level of TNF-α between T1DM patients and controls with random effects model among different ethnicity groups. Asia, SMD, 0.67, 95% CI, -1.03 to 2.36, P = 0.439; Europe, SMD, 1.30, 95% CI, 0.59 to 2.01, P < 0.001; America, SMD, 0.67, 95% CI, 0.15 to 1.18, P = 0.012; Africa, SMD, 2.07, 95% CI, 0.86 to 3.29, P = 0.001; Oceania, SMD, 1.24, 95% CI, 0.78 to 1.69, P < 0.001; Overall, SMD, 1.23, 95% CI, 0.77 to 1.68, P < 0.001.

https://doi.org/10.1371/journal.pone.0176157.g005
terminal kinase and inhibitor kinase, could cause serine/threonine phosphorylation of the insulin receptor substrate, interfere with normal phosphorylation of tyrosine, and weaken signal transduction of insulin, resulting in insulin resistance [36], otherwise, TNF-α may be result in the destruction of pancreatic beta cells and lead to the development of T1DM [59].

Age, disease duration and ethnicity of T1DM patients were focused on in this study. In a previous study [60], serum TNF-α level was not associated with the presence and severity of microalbuminuria, otherwise, the level of urinary TNF-α was only significantly influenced by albumin-creatinine ratio (ACR), although other factors had been included in the multivariate analysis: age, duration of diabetes, BMI, history of cardiovascular disease, presence of retinopathy, hypertension, and HbA1c levels. Lo, H. C., et al. [23] found that serum concentrations of TNF-α had no significant change in type 1 diabetic children compared with healthy siblings between different age groups (1–6 years old group, 6–12 years old group and 12–18 years old group), which was inconsistent with our findings. Small sample size and different statistical approach maybe illuminate the phenomenon. Ethnicity maybe another impact factor for the level of TNF-α and no significant change existed in Asia populations. In this multifactorial disease, Asia populations with varied geographic distribution, linked to climate, diet, lifestyle and economic status may contribute to the discrepancy.

Significant heterogeneity still existed after subgroups analysis and regression analysis indicated that these factors were not potential sources for the high heterogeneity, and we assume that sources of heterogeneity may be attributed to the diversity in design, sample sizes, measurement errors and so on. Otherwise, sensitivity analysis indicated the results were stable and no publication bias existed in this meta-analysis.

Several limitations should be considered when cautiously interpreting the results. Firstly, we could not conduct further subgroup analyses such as by gender, body weight and other factors because of insufficient original data. Secondly, only reports in English and reports in Chinese were chosen and eligible studies might have not been unpublished or published in other languages. Small sample size, limited statistical power and high heterogeneity of the included studies could also influence the results. Furthermore, some reports included in this meta-analysis failed to disclose the status of diabetic complications, which may have impact on the results. All these limitations should be kept in mind when interpreting the findings.

https://doi.org/10.1371/journal.pone.0176157.g006
In summary, the present meta-analysis indicates that compared with the healthy controls, the T1DM patients have significantly increased serum level of TNF-α. The role of TNF-α in the development of diabetes and diabetic complications warrant future investigation.

Supporting information
S1 Appendix. The references of the data source with DOI and access no. (DOC)
S1 Table. PRISMA 2009 checklist. (DOC)

Author Contributions
Conceptualization: YCQ.
Data curation: YCQ YLC.
Formal analysis: YCQ YLC YHP FT YX.
Funding acquisition: HLZ.
Investigation: YCQ YLC YHP FT YX XXZ.
Methodology: YCQ HLZ.
Project administration: YCQ.
Resources: HLZ.
Software: HLZ.
Writing – original draft: YCQ HLZ.
Writing – review & editing: YCQ HLZ.

References
1. Poplawska-Kita A, Siewko K, Szpak P, Krol B, Telejko B, Klimiuk PA, et al. Association between type 1 diabetes and periodontal health. Advances in medical sciences. 2014; 59(1):126–31. Epub 2014/05/07. https://doi.org/10.1016/j.advms.2014.01.002 PMID: 24797988
2. Saxena M, Srivastava N, Banerjee M. Association of IL-6, TNF-alpha and IL-10 gene polymorphisms with type 2 diabetes mellitus. Molecular biology reports. 2013; 40(11):6271–9. Epub 2013/09/24. https://doi.org/10.1007/s11033-013-2739-4 PMID: 24057184
3. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40(11):1286–92. https://doi.org/10.1007/s001250050822 PMID: 9389420
4. Festa A, D’Agostino R Jr., Howard G, Mykk nen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102(1):42–7. PMID: 10880413
5. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine reviews. 2003; 24(3):278–301. Epub 2003/06/06. https://doi.org/10.1210/er.2002-0010 PMID: 12788800
6. Borges AP, Guidoni CM, Freitas O, Pereira LR. Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. Arquivos brasileiros de endocrinologia e metabolologia. 2011; 55(9):686–91. PMID: 22231970
7. Alexandraki KI, Piperi C, Zikas PD, Apostolopoulos NV, Makrilakis K, Syriou V, et al. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. Journal of clinical Immunology. 2008; 28(4):314–21. Epub 2008/01/29. https://doi.org/10.1007/s10875-007-9164-1 PMID: 18224429
10.1016/j.jdiacomp.2014.07.004 PMID: 25113439

Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes care. 2001; 24(5):956–7. PMID: 11347765

Oghagbon EK, Jimoh KA, Olaosebikan O, Harbige L. Increased central adiposity may not underlie the marked elevation of IL-6 in diabetes mellitus patients in South-West, Nigeria. West African journal of medicine. 2014; 33(2):130–5. Epub 2014/09/23. PMID: 25236830

Duarte PM, Miranda TS, Lima JA, Dias Goncalves TE, Santos VR, Bastos MF, et al. Expression of immune-inflammatory markers in sites of chronic periodontitis in patients with type 2 diabetes. Journal of periodontology. 2012; 83(4):426–34. https://doi.org/10.1902/jop.2011.110324 PMID: 21859322

Hara Cde C, Franca EL, Fagundes DL, de Queiroz AA, Rudge MV, Honorio-Franca AC, et al. Characterization of Natural Killer Cells and Cytokines in Maternal Placenta and Fetus of Diabetic Mothers. Journal of immunology research. 2016; 2016:7154524. Epub 2016/06/14. PubMed Central PMCID: PMCPMC4884836. https://doi.org/10.1155/2016/7154524 PMID: 27294162

Flores L, Nat S, Hernaæz R, Congel I, Gomis R, Esmatæs E. Transforming growth factor beta at clinical onset of Type 1 diabetes mellitus. A pilot study. Diabetic medicine: a journal of the British Diabetic Association. 2004; 21(8):818–22.

Karavanaki K, Kakleas K, Georga S, Bartzeliotou A, Mavropoulos G, Tsouvalas M, et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoadiposis. Clinical biochemistry. 2012; 45(16–17):1383–8. https://doi.org/10.1016/j.clinbiochem.2012.05.003 PMID: 22584003

Gahring LC, Carlson NG, Kulmar RA, Rogers SW. Neuronal expression of tumor necrosis factor alpha in the murine brain. Neuroimmunomodulation. 1996; 3(5):289–303. PMID: 9218250

Hotamisliligí GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. The Journal of clinical investigation. 1994; 94(4):1534–9. Epub 1994/10/01. PubMed Central PMCID: PMCPMC295304. https://doi.org/10.1172/JCI117495 PMID: 7523453

Hotamisliligí GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994; 43(11):1271–8. Epub 1994/11/01. PMID: 7926300

Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. The Journal of biological chemistry. 1993; 268(35):26055–8. PMID: 8253716

Van Lint J, Agostinis P, Vandevooorde V, Haegeman G, Fiers W, Merlevede W, et al. Tumor necrosis factor-alpha stimulates multiple serine/threonine protein kinases in Swiss 3T3 and L929 cells. Implication of casein kinase-2 and extracellular signal-regulated kinases in the tumor necrosis factor signal transduction pathway. The Journal of biological chemistry. 1992; 267(36):25916–21. PMID: 1281478

Lechleitnér M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. Journal of internal medicine. 2000; 248(1):67–76. Epub 2000/08/18. PMID: 10947883

Pertynska-Marczewska M, Glowacka E, Grodzicka A, Sobczak M, Cypryk K, Wilczynski JR, et al. Profile of peripheral blood neutrophil cytokines in diabetes type 1 pregnant women and its correlation with selected parameters in the newborns. American journal of reproductive immunology (New York, NY: 1989). 2010; 63(2):150–60. Epub 2009/12/31.

Lo HC, Lin SC, Wang YM. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clinical biochemistry. 2004; 37(8):666–72. Epub 2004/08/11. https://doi.org/10.1016/j.clinbiochem.2004.02.002 PMID: 15302608

El-Samahy MH, Adly AA, Ismail EA, Salah NY. Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications. Journal of diabetes and its complications. 2015; 29(1):120–6. Epub 2014/08/13. https://doi.org/10.1016/j.jdiacomp.2014.07.004 PMID: 25113439

Araya AV, Pavez V, Perez C, Gonzalez F, Cylumbo A, Aguirre A, et al. Ex vivo lipopolysaccharide (LPS)-induced TNF-alpha, IL-1beta, IL-6 and PGE2 secretion in whole blood from Type 1 diabetes mellitus patients with or without aggressive periodontitis. European cytokine network. 2003; 14(3):128–33. Epub 2003/12/06. PMID: 14656685
26. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54(5):1407–14. Epub 2005/04/28. PMID: 15855327

27. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery. 2010; 8(5):336–41. https://doi.org/10.1016/j.ijsu.2010.02.007 PMID: 20171303

28. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation (PDF). Geneva: World Health Organization. 2006:21.

29. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses 2011. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003; 327(7414):557–60. PubMed Central PMCID: PMC192859. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120

31. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Statistics in medicine. 1995; 14(4):395–411. PMID: 7746979

32. Su PF, Chen X, Chen H, Shyr Y. Statistical aspects of omics data analysis using the random compound covariate. BMC systems biology. 2012; 6 Suppl 3:S11. PubMed Central PMCID: PMC3524312.

33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7(3):177–88. PMID: 3802833

34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997; 315(709):629–34. PubMed Central PMCID: PMC2127453. PMID: 9310563

35. Hegazy SK, Tolba OA, Mostafa TM, Eid MA, El-Afify DR. Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes. The review of diabetic studies: RDS. 2013; 10(1):58–67. Epub 2013/11/01. PubMed Central PMCID: PMCPMC3932072. https://doi.org/10.1900/RDS.2013.10.58 PMID: 24172699

36. Yuan T, Zhao WG, Sun Q, Fu Y, Dong YY, Dong YX, et al. Association between four adipokines and insulin sensitivity in patients with obesity, type 1 or type 2 diabetes mellitus, and in the general Chinese population. Chinese medical journal. 2010; 123(15):2018–22. Epub 2010/09/08. PMID: 20819535

37. Talaat IM, Nasr A, Alsulaimani AA, Alghamdi H, Almalki DM, et al. Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes. Journal of endocrinological investigation. 2016. Epub 2016/08/20.

38. Balic I, Angel B, Codner E, Carrasco E, Perez-Bravo F. Association of CTLA-4 polymorphisms and clinical-immunologic characteristics at onset of type 1 diabetes mellitus in children. Human immunology. 2009; 70(2):116–20. Epub 2009/01/13. https://doi.org/10.1016/j.humimm.2008.12.007 PMID: 19136037

39. Machnica L, Deja G, Polanska J, Czupryniak L, Szymanska-Garbacz E, Loba J, et al. Blood pressure disturbances and endothelial dysfunction markers in children and adolescents with type 1 diabetes. Atherosclerosis. 2014; 237(1):129–34. Epub 2014/09/23. https://doi.org/10.1016/j.atherosclerosis.2014.09.006 PMID: 25238220

40. Romano M, Pomilio M, Vigneri S, Falco A, Chiesa PL, Chiarelli F, et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes care. 2001; 24(9):1674–8. Epub 2001/08/28. PMID: 11522718

41. Mitrovic M, Ilic T, Stokic E, Paro JN, Naglic DT, Bajkin I, et al. Influence of glucoregulation quality on C-reactive protein, interleukin-6 and tumor necrosis factor-alpha level in patients with diabetes type 1. Vojnosanitetski pregled. 2011; 68(9):756–61. Epub 2011/11/04. PMID: 22046880

42. Pham MN, Hawa MI, Pfleger C, Roden M, Schernthaner G, Pozzilli P, et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia. 2011; 54(7):1630–8. Epub 2011/02/25. https://doi.org/10.1007/s00125-011-2088-6 PMID: 21347621

43. Martos-Morén GA, Barrios V, Soriano-Guillén L, Argente J. Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. European journal of endocrinology / European Federation of Endocrine Societies. 2006; 155(5):757–61. Epub 2006/10/26.

44. Aguilera E, Serra-Planas E, Granada ML, Pellitero S, Reverter JL, Alonso N, et al. Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population. Cardiovascular diabetology. 2015; 14:121. Epub 2015/09/19. PubMed Central PMCID: PMCPMC4574547. https://doi.org/10.1186/s12933-015-0287-z PMID: 26382922
45. Gabbay MA, Sato MN, Duarte AJ, Dib SA. Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clinical and experimental immunology. 2012; 168(1):60–7. Epub 2012/03/06. PubMed Central PMCID: PMCPMC3390495. https://doi.org/10.1111/j.1365-2249.2011.04538.x PMID: 22385239

46. Abdel Aziz MT, Fouad HH, Mohsen GA, Mansour M, Abdel Ghaffar S. TNF-alpha and homocysteine levels in type 1 diabetes mellitus. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2001; 7(4–5):679–88. Epub 2004/08/31.

47. Lv L, Liu JY, Ma J, Lin SX, Huang L. [Factors associated with Th1 cytokine disorders in children with newly diagnosed type 1 diabetes]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2013; 15(1):50–2. Epub 2013/01/23. PMID: 23336169

48. Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of the glycemic control on intracelluar cytokine production from peripheral blood mononuclear cells of type 1 and type 2 diabetic patients. Diabetes research and clinical practice. 2008; 82(3):329–34. Epub 2008/10/14. https://doi.org/10.1016/j.diabres.2008.09.003 PMID: 18849088

49. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annual review of immunology. 1993; 11:767–804. https://doi.org/10.1146/annurev.iy.11.040193.004003 PMID: 8476577

50. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity. 1998; 22(12):1145–58. Epub 1999/01/07.

51. Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. Journal of internal medicine. 2001; 250(5):415–21. Epub 2002/03/13. PMID: 11887976

52. Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. In vitro TNF-alpha and IL-6 production by adherent peripheral blood mononuclear cells obtained from type 1 and type 2 diabetic patients evaluated according to the metabolic control. Annals of the New York Academy of Sciences. 2006; 1079:177–80. https://doi.org/10.1196/annals.1375.027 PMID: 17130551

53. Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of metabolic control on interferon-gamma and interleukin-10 production by peripheral blood mononuclear cells from type 1 and type 2 diabetic patients. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al]. 2007; 40(5):671–7. PubMed

54. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS immunology and medical microbiology. 1999; 26(3–4):259–65. PMID: 10575137

55. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (New York, NY). 1993; 259(5091):87–91. Epub 1993/01/01.

56. Neish AS, Read MA, Thanos D, Pine R, Maniatis T, Collins T. Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1. Molecular and cellular biology. 1995; 15(5):2558–69. PubMed Central PMCID: PMC230486. PMID: 7537851

57. De Mattia G, Bravi MC, Costanzo A, Laurenti O, Cassone Faldetta M, Armiento A, et al. Effects of insulin on in vitro vascular cell adhesion molecule-1 expression and in vivo soluble VCAM-1 release. Diabetologia. 1999; 42(10):1235–9. PMID: 10525665

58. Deisher TA, Haddix TL, Montgomery KF, Pohlan TH, Kaushansky K, Harlan JM. The role of protein kinase C in the induction of VCAM-1 expression on human umbilical vein endothelial cells. FEBS letters. 1993; 331(3):285–90. PMID: 7690717

59. Iacopino AM. Periodontitis and diabetes interrelationships: role of inflammation. Annals of periodontology / the American Academy of Periodontology. 2001; 6(1):125–37. Epub 2002/03/13.

60. Lampropoulou IT, Stangou M, Papagianni A, Didangelos T, Iliadis F, Efstratiadi G. TNF-alpha and microalbuminuria in patients with type 2 diabetes mellitus. Journal of diabetes research. 2014; 2014:394206. Epub 2015/01/15. PubMed Central PMCID: PMCPMC4284977. https://doi.org/10.1155/2014/394206 PMID: 25587544